**Background:** Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death globally and in Jordan, accounting for approximately 37% of total deaths in Jordan in 2018. Dyslipidemia is a major modifiable risk factor, with a prevalence in Jordan ranging from 75.7% to 81.6% in cohort studies between 2006 and 2022, far exceeding the European prevalence of about 20.8%. Existing international guidelines are based on Western populations and may not be directly applicable to Jordanians due to differences in baseline demographics, risk factor prevalence, and statin eligibility. This consensus statement was developed by a multidisciplinary panel of Jordanian experts to provide locally relevant recommendations.
**Methods:** A panel of experts from multiple Jordanian medical societies (cardiology, endocrinology, nephrology, internal medicine, general practice, nutrition) conducted an extensive literature review using PubMed, Web of Science, Medline, Scopus, and EMBASE. Keywords included 'dyslipidemia', 'hyperlipidemia', 'hypercholesterolemia', 'screening', 'risk category', 'cardiovascular risk', 'treatment', 'management', 'lipid-lowering therapy', and 'safety of pharmacotherapy'. The panel reviewed international guidelines and studies on ASCVD and lipid disorders in Jordan. Recommendations were discussed and amended until unanimous agreement was reached.
**Key Results:** The panel proposed a five-step approach: (1) Screening for dyslipidemia in all Jordanians aged 20 years or older, with repeat testing every 5 years if normal; earlier screening for those with conditions like diabetes, hypertension, smoking, or family history. (2) Lipid profile measurement can be fasting or non-fasting; if non-fasting triglycerides are ≥400 mg/dL, a fasting sample is needed. (3) Risk categorization using SCORE2/SCORE2-OP charts for very high-risk regions (e.g., Lebanon, Egypt) for apparently healthy individuals, and predefined categories (extremely high, very high, high, moderate, low) based on clinical disease. (4) LDL-C treatment targets: extremely high risk <40 mg/dL, very high risk <55 mg/dL, high risk <70 mg/dL, moderate risk <100 mg/dL, low risk <116 mg/dL. (5) Management includes lifestyle modifications (diet, exercise, smoking cessation) and pharmacotherapy: statins as first-line (high-intensity for ≥50% LDL-C reduction), ezetimibe added if targets not met after 3 months, and PCSK9 inhibitors (evolocumab) or inclisiran for those not achieving goals or intolerant to statins. For hypertriglyceridemia >500 mg/dL, fibrates or omega-3 fatty acids are recommended to prevent pancreatitis.
**Clinical Implications:** These guidelines provide a standardized, evidence-based framework for managing dyslipidemia in Jordan, aiming to reduce the high burden of ASCVD. The adoption of SCORE2/SCORE2-OP charts for very high-risk regions and the inclusion of an extremely high-risk category with aggressive LDL-C targets reflect the need for intensive lipid lowering in this population. The stepwise pharmacotherapy algorithm emphasizes achieving LDL-C goals with a combination of lifestyle changes and medications, including newer agents like inclisiran. Implementation of these recommendations could improve cardiovascular outcomes and align clinical practice in Jordan with international standards while accounting for local epidemiological and demographic characteristics.